Clinical Trial Detail

NCT ID NCT03468985
Title Nivolumab, Cabozantinib S-Malate, and Ipilimumab in Treating Patients With Recurrent Stage IV Non-small Cell Lung Cancer
Recruitment Suspended
Gender both
Phase Phase II
Variant Requirements yes
Sponsors National Cancer Institute (NCI)
Indications

non-small cell lung carcinoma

Therapies

Cabozantinib + Nivolumab

Cabozantinib + Ipilimumab + Nivolumab

Nivolumab

Age Groups: adult senior

Additional content available in CKB BOOST